Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Safety and Arrhythmia Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SCN5A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCN5A Extracellular Loop Peptides / Recombinant Fragment High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View SCN5A Products |
| Gene Delivery | SCN5A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native 24-TM conformation. |
View SCN5A Products |
| Benchmark Ab | Anti-SCN5A Recombinant Antibody Recombinant positive control for expression validation. |
View SCN5A Products |
| Validator | SCN5A siRNA Set For target knockdown verification in functional assays. |
View SCN5A Products |
| Related Target A | KCNH2 (hERG) Essential partner in the core cardiac safety tri-channel panel (hERG, Nav1.5, Cav1.2). |
View KCNH2 Products |
| Related Target B | SCN9A (Nav1.7) Critical homolog for subfamily selectivity screening to avoid cardiac off-target toxicity. |
View SCN9A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation preservation of 24-TM channel | High-titer Lentiviral Particles for stable, functional cell line development in HEK293/CHO-K1. |
| Subfamily selectivity screening (Nav1.5 vs Nav1.7) | Sequence-verified ORF Lentivirus panel covering major voltage-gated sodium channels. |
| Lack of Controls | Sequence-verified recombinant reference antibodies included. |
| False Positives | Pre-validated siRNA sets included for target knockdown specificity checks. |
Live SCN5A/Nav1.5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SCN5A (Nav1.5) landscape represents a dual-nature pillar in drug discovery. On one hand, Nav1.5 is a primary cardiac safety target governed by regulatory guidelines (ICH S7B), requiring rigorous off-target profiling for almost all small molecule pipelines. On the other hand, it serves as a therapeutic target for cardiac channelopathies, such as Brugada syndrome and Long QT Syndrome Type 3 (LQT3).
The race for SCN5A therapeutics is intensifying, with major players shifting focus from traditional non-selective anti-arrhythmics to isoform-selective small molecule modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting precision mutations (e.g., DeltaKPQ) and leveraging stable overexpressing cell lines for high-throughput automated patch-clamp screening.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Safety Screening) | All Pharmaceutical Developers | Cardiotoxicity Profiling | Automated Patch Clamp (Need high-efficiency Lentivirus for stable cell line generation) |
| Small Molecule (Therapeutic) | Gilead, Xenon Pharmaceuticals | LQT3, Cardiac Arrhythmias | Selectivity Assay (Need comparative SCN1A/SCN9A cell line tools to avoid off-target side effects) |
| Gene Therapy / RNA Modulators | Academic Institutes, Biotech Startups | Brugada Syndrome, Channelopathies | Target Knockdown Verification (Need validated siRNA and sequence-verified ORF) |